Description
Tradename:
Imigran
Compound:
Each tablet contains:
sumatriptan 50 mg
Auxiliary components:
Lactose, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, purified water.
Properties:
Sumatriptan is a specific selective agonist of 5-HT1-serotonin receptors, localized primarily in the blood vessels of the brain and their stimulation leads to a narrowing of these vessels. Does not affect other subtypes of 5-HT-serotonin receptors (5-HT2-7). Activates the sensitivity of trigeminal nerve receptors. The therapeutic effect usually occurs 30 minutes after administration.
Indications:
Migraine attack with or without aura.
Directions for use and dosage:
Inside, the tablet should be swallowed whole with water. Treatment should be started as early as possible when a migraine attack occurs. The recommended dose is 50 mg, if necessary – 100 mg.
If migraine symptoms do not disappear or decrease after taking the first dose, then the drug should not be used again to relieve the same attack.
To relieve subsequent attacks (if symptoms decrease or disappear and then recur), you can take a second dose within the next 24 hours, provided that the interval between doses is at least 2 hours.
The maximum daily dose is 300 mg.
Contraindications:
– hemiplegic, basilar or ophthalmoplegic forms of migraine;
-FIBS or the presence of symptoms suggesting its presence;
– history of myocardial infarction;
– pharmacologically uncontrolled arterial hypertension;
-occlusive diseases of peripheral vessels;
-stroke or transient cerebrovascular accident (including history);
– severe dysfunction of the liver and kidneys;
-simultaneous administration with ergotamine or its derivatives and within 24 hours after their administration;
– use while taking monoamine oxidase inhibitors or earlier than 2 weeks after discontinuation of these drugs;
– age under 18 and over 65 years (efficacy and safety have not been established);
-pregnancy;
-breastfeeding (breastfeeding is possible no earlier than 24 hours after taking the drug);
-congenital galactosemia, glucose/galactose malabsorption syndrome, congenital lactose deficiency;
– hypersensitivity to any of the components of the drug.
Precautionary measures:
Do not use to prevent a migraine attack.
Patients at risk for the cardiovascular system should not begin therapy without prior examination (postmenopausal women, men over 40 years of age, persons with risk factors for coronary artery disease). Before prescribing sumatriptan to patients with newly diagnosed or atypical migraine, other potentially dangerous neurological diseases should be excluded. Chest pain and tightness may occur after taking sumatriptan. The pain can be intense and radiate to the neck. If there is reason to believe that these symptoms are a manifestation of coronary artery disease, it is necessary to conduct an appropriate examination.
Side effects:
From the nervous system: often – dizziness, drowsiness, sensory disturbances, including parasthesia and decreased sensitivity.
From the cardiovascular system: often – a transient increase in blood pressure (observed soon after taking the drug), “hot flashes”.
From the respiratory system and respiratory organs: often – dyspnea, mild, transient irritation of the mucous membrane or a burning sensation in the nasal cavity or throat, nosebleeds.
From the gastrointestinal tract: often – nausea, vomiting.
From the musculoskeletal system and connective tissue: often – a feeling of heaviness (usually transient, can be intense and occur in any part of the body, including the chest and throat).
General and local reactions: often – pain, a feeling of cold or heat, a feeling of pressure or tightness (usually transient, can be intense and occur in any part of the body, including the chest and throat), weakness, fatigue (usually mild or moderate, transitory).
